P2Add image
PNC-27
LongevitySingleA synthetic peptide containing an HDM-2 binding region of p53 fused to a membrane-residence sequence, studied in oncology research as a selective cancer-cell membrane-disrupter.
Half-life
—
Common dose
1 – 5 mg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
PNC-27 binds HDM-2 expressed on cancer-cell membranes and forms pores, lysing the cell. Selectivity is based on cancer cells' overexpression of membrane HDM-2 vs. healthy cells.
Protocol notes
Highly experimental. No established human-use protocols. Preclinical evidence only.
Reported side effects
Limited human safety data. Highly experimental.